Celecoxib for ENT Pain Management

Description

The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tylenol to a placebo to find out whether celecoxib works to manage pain. Participants will: * Take celecoxib, or a placebo, plus Tylenol with opioids as needed * Keep a diary of their pain between visits * Complete questionnaires

Conditions

Parotidectomy

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to find out whether pain can be managed after an operation with celecoxib instead of oxycodone. The main question it aims to answer is if use of celecoxib plus Tylenol reduces the need for oxycodone. Researchers will compare the combination of celecoxib and Tylenol to a placebo to find out whether celecoxib works to manage pain. Participants will: * Take celecoxib, or a placebo, plus Tylenol with opioids as needed * Keep a diary of their pain between visits * Complete questionnaires

Celecoxib Pain Management Following Superficial Parotidectomy: Opioid Sparing Protocol

Celecoxib for ENT Pain Management

Condition
Parotidectomy
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53702

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to understand and the willingness to sign a written informed consent document
  • * Willing to comply with all study procedures and be available for the duration of the study
  • * Ability to take oral medication
  • * Undergoing superficial parotidectomy
  • * Individuals at least 18 years of age
  • * Adequate organ function as indicated by standard laboratory tests: hematology (complete blood count), clinical chemistry
  • * History of NSAIDs contraindication (severe congestive heart failure, CABG within 14 days, arrhythmias, significant coronary artery disease, cardiomyopathy, severe hepatic impairment, history of peptic ulcer disease or GI bleeding, use of anticoagulation (other than prophylactic aspirin)
  • * History of uncontrolled hypertension, cerebrovascular accident, sulfa allergy, allergy to celecoxib
  • * Concurrent use of CYP2C9 potentiator/inhibitor
  • * Use of investigational drugs, biologics, or devices within 30 days prior to randomization.
  • * Individuals who are pregnant, lactating or planning on becoming pregnant during the study.
  • * Not suitable for study participation due to other reasons at the discretion of the investigators.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Tiffany Glazer, MD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2026-09